Maxion Therapeutics

Maxion Therapeutics is a biotechnology company developing a pipeline of KnotBody therapeutics for diseases driven by ion channel and G protein-coupled receptor dysfunction.

The platform combines naturally occurring mini-proteins with antibodies to generate potent, selective and long-acting biologics against target classes previously inaccessible to antibody drug discovery. Lead programme MAX001 is in preclinical development for inflammatory diseases including atopic dermatitis.

The company raised £58 million in a Series A financing in March 2025.